Close Menu

NEW YORK — Proteomics firm Seer said today that it has closed a $55 million Series D funding round.

The company plans to use the funds to develop and commercialize its Proteograph proteomics platform for research and clinical applications. According to the company the platform allows for proteomics at a scale and speed not possible with existing platforms.

The round was led by life science venture capital fund aMoon with participation from existing and other new investors.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

At the Lancet, more than two dozen public health researchers condemn the conspiracy theories that have emerged surrounding the source of the COVID-19 outbreak.

The Washington Post reports that Philip Leder, who helped uncover how DNA codes for proteins and studied the role of genes in cancer, has died.

Researchers from Trinity College Dublin and the University of Pittsburgh look into how often de novo genes arise and how important they may be.

In Nucleic Acids Research this week: pipeline for genotyping Alu retrotransposon mobile element insertions, previously undocumented non-coding RNAs, and more.

Sponsored by

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.